AI English summary of an SEC filing — figures as filed
Agilent Technologies AAgilent said it reorganized its operating structure into three business groups: the Life Sciences and Diagnostics Markets Group, the Applied Markets Group and the Agilent CrossLab Group, effective November 25, 2024. The new structure includes new leadership roles and takes effect immediately.
Key points
AI summaryAgilent said it reorganized its operating structure into three business groups: the Life Sciences and Diagnostics Markets Group, the Applied Markets Group and the Agilent CrossLab Group, effective November 25, 2024. The new structure includes new leadership roles and takes effect immediately.
The company gave its estimated shares of fiscal year 2024 revenue as follows: LDG 38%, AMG 20% and ACG 42%. It said LDG focuses on pharma, biopharma, clinical and diagnostics, AMG on food, environmental, forensics, chemicals and advanced materials, and ACG on supporting customers across all end markets.
Agilent said Simon May will serve as president of LDG and Mike Zhang has been promoted to president of AMG, while Angelica Riemann will continue as president of ACG. It said Phil Binns, former president of the Life Sciences and Applied Markets group, will retire in April 2025.
The company said it will report results under the new structure starting with its first-quarter 2025 results, while its fourth-quarter fiscal 2024 results, released the same day, will be reported under the existing structure. It also plans to file an 8-K with recast financial reporting for the past 3 years before its Analyst and Investor Day, and to release a recast 10-K reflecting the new structure in March 2025.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Agilent Reorganizes Into Three Business Groups
Agilent said it reorganized its operating structure into three business groups: the Life Sciences and Diagnostics Markets Group, the Applied Markets Group and the Agilent CrossLab Group, effective November 25, 2024. The new structure includes new leadership roles and takes effect immediately.
Source · Based on the filing body and exhibits
Business Group Revenue Shares and Coverage
The company gave its estimated shares of fiscal year 2024 revenue as follows: LDG 38%, AMG 20% and ACG 42%. It said LDG focuses on pharma, biopharma, clinical and diagnostics, AMG on food, environmental, forensics, chemicals and advanced materials, and ACG on supporting customers across all end markets.
Source · Based on the filing body and exhibits
Business Group Leadership Appointments
Agilent said Simon May will serve as president of LDG and Mike Zhang has been promoted to president of AMG, while Angelica Riemann will continue as president of ACG. It said Phil Binns, former president of the Life Sciences and Applied Markets group, will retire in April 2025.
Source · Based on the filing body and exhibits
Reporting Structure Change Timeline
The company said it will report results under the new structure starting with its first-quarter 2025 results, while its fourth-quarter fiscal 2024 results, released the same day, will be reported under the existing structure. It also plans to file an 8-K with recast financial reporting for the past 3 years before its Analyst and Investor Day, and to release a recast 10-K reflecting the new structure in March 2025.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…